Eastman Chemical heads into its May 7 Q1 print with options traders taking a notably more optimistic stance than usual — a sharp reversal from the defensive posture seen just days ago.
The options signal is the clearest standout in the pre-earnings setup. The put/call ratio dropped to 0.42 on May 4, more than two standard deviations below its 20-day average of 0.62. That reading is close to the lowest of the past year, and it arrived after the PCR spent most of April running near its 52-week high of 0.72 — heavy put demand that has now unwound with unusual speed. The message from options positioning is that investors have rotated from hedging into expressing directional upside into the print.
The shift in options tone coincides with a wave of analyst target increases on the day before earnings. JP Morgan's Jeffrey Zekaukas raised his target to $82 from $80, maintaining Overweight — a continuation of an upgrade he made from Neutral in mid-April when the stock was under pressure. Citigroup lifted to $88 from $83, keeping its Buy. Wells Fargo moved its Equal-Weight target to $80 from $70. Three separate upward revisions on a single session signal the Street is recalibrating higher, not hedging lower, ahead of the release. The consensus mean target now sits near $84, roughly 9% above the current $76.72 close. The bull case centres on Eastman's specialty mix — approximately 70% of the portfolio in higher-margin businesses — and expected pricing improvements in Additives, Functional Products and Advanced Materials, alongside growth in Asian markets. Bears point to a P/E of 11.7x, well below specialty chemical peers, as a signal the market remains sceptical that the specialty story fully offsets lingering commodity exposure and episodic demand softness in Tow.
Short interest frames the setup as undemanding for bears. At 4.2% of free float, it has declined nearly 3% over the past week and retreated steadily from a local peak of roughly 5% in mid-April. Borrowing costs are low at 0.55%, and availability in the lending market remains ample — utilisation has eased from its year-to-date peak of 14.6% in early April to below 8% now. The ORTEX short score of 38.9 ranks in the 26th percentile of the universe, confirming that this is not a heavily contested name. The week-on-week recovery in the share price — up 6.4% to $76.72 — is broadly in line with peers: HUN gained 7.4% and KRO surged 10.7% over the same stretch, suggesting the move reflects a sector-wide relief trade rather than EMN-specific re-rating.
The May 7 print will test whether the specialty portfolio's pricing and volume trajectory can justify the analyst target upgrades and the sharp reversal in options sentiment — or whether the low valuation multiple reflects structural scepticism that stronger-than-expected results alone cannot easily dislodge.
See the live data behind this article on ORTEX.
Open EMN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
